Investigation of the Differences between the Immunity of High- and Low-risk Anatomical Regions in Patients with Basal Cell Carcinoma: Is Neutrophil to Lymphocyte Ratio Associated with Regional Distribution of the Tumor?

OBJECTIVE Basal cell carcinoma (BCC) is the most commonly observed type of cancer. Neutrophil-to-lymphocyte ratio (NLR) is a measure of the immune status of patients, and the ratio increases as the tumor becomes aggressive. This study aims to compare the NLR of patients with tumors in high-risk H region and in the usual risk regions. METHODS Patients who were operated for BCC between January 2017 and May 2018 were included in this study. Patients were divided into two groups. Patients with tumors found in the high-risk H region, according to subclinical expansion, were classified as Group 1. Patients with tumors in other anatomical regions were classified as Group 2. Electronic file and photographs of each patient from the archives were examined and demographical data, as well as hemogram analyses, were recorded. RESULTS CONCLUSION Forty-six cases were included in this study. Fourteen patients were female and 32 patients were male. T he mean age of the patients was 64,6 years (33–87 years). The mean follow-up period was eight months (1-17 months). The NLR and thrombocyte to lymphocyte ratio of the patients did not show statistically significant differences between the groups (p>0.05). T he NLR does not distinguish between the H region and other regions in BCC concerning biological characteristics of the tumor.

PDF

___

1. Rigel DS, Friedman RJ, Kopf AW. Lifetime risk fordevelopment of skin cancer in the U.S. population: currentestimate is now 1 in 5. J Am Acad Dermatol 1996;35(6):1012–3.
2. Marzuka AG, Book SE. Basalcellcarcinoma: pathogenesis, epidemiology, clinicalfeatures, diagnosis, histopathology, andmanagement. Yale J Biol Med 2015;88(2):167–79.
3. Correia de Sá TR, Silva R, Lopes JM. Basalcellcarcinoma of the skin (part 1): Epidemiologypathologyandgeneticsyndromes. Future Oncol 2015;11(22):3011–21.
4. Baxter JM, Patel AN, Varma S. Facial basal cell carcinoma. BMJ 2012;345:e5342.
5. Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002;138(8):1043–51.
6. Margo CE, Waltz K. Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol 1993;38(2):16992.
7. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes 2017;10(1):12.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008;454(7203):436–44.
9. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014 29;106(6):dju124.
10. Baykan H, Cihan YB, Ozyurt K. Roles of White blood cells and subtypes as inflammatorymarkers in skin cancer. Asian Pac J Cancer Prev 2015;16(6):2303–6.
11. Muzic JG, Schmitt AR, Wright AC, Alniemi DT, Zubair AS, Olazagasti Lourido JM, et al. Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc 2017;92(6):890–8.
12. Skin cancers. World HealthOrganizationWebsite. Available at: http://www.who.int/uv/faq/skincancer/ en/index1.html. Accessed Feb 3, 2020.
13. Choi JH, Kim YJ, Kim H, Nam SH, Choi YW. Distribution of Basal cell carcinoma and squamous cell carcinoma by facial esthetic unit. Arch Plast Surg 2013;40(4):387–91.
14. Kim JW, Oh CH, Kim IH. Distribution of histologic subtypes of basal cell carcinoma by facial aesthetic unit and subunit. Korean J Dermatol 2000;38(1):31–7.
15. Mora RG, Robins P. Basal-cell carcinomas in the center of the face: special diagnostic, prognostic, and therapeutic considerations. J Dermatol Surg Oncol 1978;4(4):315–21.
16. Grivennikov SI, Greten FR, Karin M. Immunity, inf lammation, and cancer. Cell 2010;140(6):883–99.
17. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88(1):218–30.